Related Experiment Videos
[1998 malaria therapy]
1Konsiliarius für Tropenmedizin, Departement Innere Medizin, Universitätsspital Zürich.
Schweizerische Medizinische Wochenschrift
|October 24, 1998
Summary
For malaria treatment in Switzerland, mefloquine is recommended for uncomplicated Plasmodium falciparum malaria due to widespread chloroquine resistance. Severe cases or high parasitaemia require quinine, with hospitalization advised for uncertain prognoses.
Area of Science:
- Tropical Medicine
- Pharmacology
Context:
- Switzerland faces imported malaria cases, predominantly Plasmodium falciparum.
- High prevalence of chloroquine-resistant malaria in common travel destinations poses a challenge.
Purpose:
- To provide evidence-based recommendations for malaria treatment tailored to Switzerland.
- To guide clinicians in selecting appropriate antimalarial drugs based on resistance patterns and patient factors.
Summary:
- Mefloquine is the first-line treatment for uncomplicated Plasmodium falciparum malaria imported into Switzerland, given prevalent chloroquine resistance.
- Quinine is the preferred drug for severe malaria or parasitaemia exceeding 2%.
- Treatment decisions must weigh drug resistance, clinical status, intolerance, and drug interactions. Hospitalization is recommended for uncertain cases, with consideration for ancillary treatments like exchange transfusion.
Impact:
- Optimized malaria treatment protocols for the Swiss context.
- Improved patient outcomes by addressing drug resistance and severe malaria management.
- Informed clinical decision-making for healthcare professionals treating imported malaria.